Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Neurocrine Bioscienc (NQ: NBIX ) 147.77 +1.08 (+0.74%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Neurocrine Bioscienc < Previous 1 2 3 4 5 6 7 8 Next > NASDAQ:NBIX: a strong growth stock preparing for the next leg up?. November 23, 2023 NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX): a strong growth stock preparing for the next leg up?. Via Chartmill CRISPR Therapeutics Stock Earns 88 RS Rating On U.K. Regulator News November 17, 2023 CRISPR Therapeutics sees its Relative Strength Rating enter the 80-plus level. Via Investor's Business Daily Madrigal Pharmaceuticals Stock Clears Benchmark, Hits 80+ RS Rating November 17, 2023 Madrigal Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 86. Via Investor's Business Daily Amphastar Pharmaceuticals Stock Earns Composite Rating Upgrade November 10, 2023 Amphastar Pharmaceuticals stock saw its IBD SmartSelect Composite Rating rise to 98 Friday, up from 93 the day before. Via Investor's Business Daily Why Is Neurocrine Biosciences Stock Trading Lower Today? November 10, 2023 Thursday, Neurocrine Biosciences Inc (NASDAQ: NBIX) Via Benzinga NASDAQ:NBIX stands out as a growth opportunity that won't break the bank. November 07, 2023 Don't overlook NASDAQ:NBIX—a stock with solid growth prospects and a reasonable valuation. Via Chartmill NASDAQ:NBIX: a strong growth stock preparing for the next leg up?. November 02, 2023 Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Promising High-Growth Stock in the Midst of Consolidation. Via Chartmill Earnings Outlook For Neurocrine Biosciences October 30, 2023 Via Benzinga NASDAQ:NBIX—A High-Growth Stock Gearing Up for Its Next Upward Move. October 12, 2023 Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) on the Verge of a Major Breakout as a Strong Growth Stock? Via Chartmill 3 Biotech Moonshots to Bet on the Future of Health November 06, 2023 Thanks to their potential blockbuster drugs, these three biotech stocks may yield huge returns for patent investors willing to take the risk. Via InvestorPlace Topics Intellectual Property Exposures Intellectual Property Rocket Pharmaceuticals Stock Sees Improved Price Strength November 02, 2023 On Thursday, Rocket Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 68 to 78 Via Investor's Business Daily Raymond James Maintains Outperform Rating for Neurocrine Biosciences: Here's What You Need To Know November 01, 2023 Via Benzinga Despite its growth, NASDAQ:NBIX remains within the realm of affordability. October 16, 2023 Don't overlook NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—a stock with solid growth prospects and a reasonable valuation. Via Chartmill Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout. October 11, 2023 Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Promising High-Growth Stock in the Midst of Consolidation. Via Chartmill What 22 Analyst Ratings Have To Say About Neurocrine Biosciences October 06, 2023 Via Benzinga Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout. September 28, 2023 Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Promising High-Growth Stock in the Midst of Consolidation. Via Chartmill NASDAQ:NBIX: a strong growth stock preparing for the next leg up?. September 27, 2023 NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX): a strong growth stock preparing for the next leg up?. Via Chartmill NASDAQ:NBIX qualifies as a high growth stock and is consolidating. September 26, 2023 NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—A High-Growth Stock Gearing Up for Its Next Upward Move. Via Chartmill Why Is Neurocrine Biosciences Shares Trading Higher Today? October 05, 2023 Neurocrine Biosciences Inc (NASDAQ: NBIX) released topline data from the Phase 3 CAHtalyst Pediatric Study of crinecerfont in children and adolescents with classic congenital adrenal hyperplasia (CAH)... Via Benzinga Why NASDAQ:NBIX Is a Promising High-Growth Stock in the Midst of Consolidation. September 22, 2023 Why NEUROCRINE BIOSCIENCES INC ( NASDAQ:NBIX ) Is a Promising High-Growth Stock in the Midst of Consolidation. Via Chartmill Analyst Expectations for Neurocrine Biosciences's Future September 13, 2023 Via Benzinga GoDaddy To Rally Around 44%? Here Are 10 Other Analyst Forecasts For Wednesday September 13, 2023 Needham cut the price target for Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) from $60 to $53. Needham analyst Gil Blum maintained a Buy rating. Rocket Pharmaceuticals shares rose 24.3% to $19.00 in... Via Benzinga What's Going On With Neurocrine Biosciences Stock Today? September 12, 2023 Neurocrine Biosciences Inc (NASDAQ: NBIX) announced positive topline data from the Phase 3 CAHtalyst Adult Study evaluating crinecerfont in adults with classic congenital adrenal hyperplasia (CAH) due... Via Benzinga Analyst Ratings for Neurocrine Biosciences August 21, 2023 Via Benzinga Analyst Ratings for Neurocrine Biosciences August 02, 2023 Via Benzinga Earnings Outlook For Neurocrine Biosciences July 31, 2023 Via Benzinga Can Neurocrine Erase Its Recent Setbacks With This Jump To An Eight-Month High? September 12, 2023 The company is working on a treatment for a disorder than can cause children to begin puberty early. Via Investor's Business Daily 10 Health Care Stocks With Whale Alerts In Today's Session September 08, 2023 Via Benzinga FDA Greenlights Expanded Use Of Neurocrine Biosciences' Ingrezza: Analysts Weigh In Depression Warning August 21, 2023 The FDA approved Neurocrine Biosciences Inc's (NASDAQ: NBIX) Ingrezza (valbenazine) capsules for the treatment of adults with chorea associated Via Benzinga Exposures Product Safety Confidence Boost From Ingrezza Sales: Analyst Upgrades Neurocrine Biosciences July 06, 2023 BMO Capital Markets has upgraded Neurocrine Biosciences Inc (NASDAQ: NBIX) from Underperform to Market Perform, with a price target of $96, Via Benzinga < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.